通化东宝: 通化东宝2025年半年度报告摘要

Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. reported total assets of approximately 7.85 billion RMB at the end of the reporting period, reflecting a 6.35% increase compared to the previous year [1] - The net assets attributable to shareholders decreased by 4.11% to approximately 6.12 billion RMB [1] Financial Performance - The company achieved a revenue of approximately 1.37 billion RMB, marking an 85.60% increase year-on-year [1] - Total profit reached approximately 254.93 million RMB, a significant recovery from a loss of approximately 298.33 million RMB in the previous year [1] - The net profit attributable to shareholders was approximately 217.76 million RMB, recovering from a loss of approximately 230.49 million RMB [1] - The net cash flow from operating activities increased by 147.50% to approximately 317.36 million RMB [1] - The weighted average return on net assets was 3.35%, a turnaround from -3.32% in the previous year [1] - Basic and diluted earnings per share were both 0.11 RMB, recovering from -0.12 RMB [1] Shareholder Information - The largest shareholder, Dongbao Industrial Group Co., Ltd., holds 31.13% of the shares, amounting to approximately 609.65 million shares [2] - Other significant shareholders include Tianjin Zhenyi Equity Investment Partnership with 9.35% and Abu Dhabi Investment Authority with 1.63% [2]